Loading resource…

Waichi Wong, MD
Chronic kidney disease (CKD) affects over 800 million individuals globally, leading to significant health issues. The document outlines how RAAS inhibitors have been pivotal in slowing CKD progression and improving patient outcomes. It also reviews the emergence of new therapies that provide additional benefits for kidney and cardiovascular health. Furthermore, it addresses the advancements in prognostic assessment methods, although their integration into clinical practice is still a work in progress.
Sign in to open
Answers use this document only.
Your first question is free.
Resources from the same specialty and type. Curated links will replace these when added.
Documents that extend or complement this resource.

CARDIOVASCULAR COMPLICATIONS IN CHRONIC KIDNEY DISEASE: A REVIEW FROM THE EUROPEAN RENAL AND CARDIOVASCULAR MEDICINE WORKING GROUP OF THE EUROPEAN RENAL ASSOCIATION
Same clinical topic · Nephrology

THE ASSOCIATION BETWEEN DUAL RAAS INHIBITION AND RISK OF ACUTE KIDNEY INJURY AND HYPERKALEMIA IN PATIENTS WITH DIABETIC KIDNEY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
Same clinical topic · Nephrology

OBESITY IN CKD: CORE CURRICULUM 2026
Same clinical topic · Nephrology

OBESITY IN CKD: CORE CURRICULUM 2026
Same clinical topic · Nephrology

ACUTE GLOMERULONEPHRITIS
Same clinical topic · Nephrology

DISEASE MODIFICATION IN LUPUS NEPHRITIS: TOWARDS A PATHOPHYSIOLOGY-BASED TREATMENT PARADIGM
Same clinical topic · Nephrology

Effects of correction rate for severe hyponatremia in the intensive care unit on patient outcomes
Same clinical topic · Nephrology

CURRENT UNDERSTANDING OF SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS IN CARDIOVASCULAR-KIDNEY-METABOLIC SYNDROME
Same clinical topic · Nephrology

A COMPREHENSIVE REVIEW OF ACUTE CARDIO-RENAL SYNDROME: NEED FOR NOVEL BIOMARKERS
Same clinical topic · Nephrology